Fritextsökning
Artiklar per år
Innehållstyper
-
Marie Gårdmark: ”The situation is not satisfactory”
”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration of new products in rare diseases. But will it also work to increase access for all EU patients
-
Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”
forward and thinking about all the new things that there will be in a freer role,” she says to Life Science Sweden
-
Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”
It all started with a summer job as an operator at Astra’s chemical factory in Snäckviken, just outside Södertälje. More than three decades and countless different assignments later, Per Alfredsson, born and raised in Södertälje, is CEO of Astra Zeneca
-
The Swedish government is to increase its investment in cancer care
The Swedish government wants to invest more in cancer and paediatric cancer care and proposes to allocate SEK 500 million per year for this purpose in the coming years.
-
From the sea of Åland to a self-test for lithium
Four years ago, a meeting on the sea of Åland resulted in the development of a self-test for lithium levels in the blood. The hopes are that the test will be available for individuals with bipolar disorder in the future.
-
Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients
In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.
-
Heidi Stensmyren is eager for new challenges in the biotech industry
Heidi Stensmyren has served as President of the Swedish Medical Association, held a managerial position at Karolinska University Hospital and is now Medical Director at a biotech company. “I’m curious and like to have influence, so I’ve often chosen management roles,” she says.
-
Here are the pharmaceutical companies best prepared for AI
How well prepared are pharmaceutical companies in the field of artificial intelligence? That is what a new analysis has tried to evaluate.
-
Life Science Sweden heads to the Oresund region! ‒ Hello there Michael Linnell
Life Science Sweden’s The Future of Swedish Danish Life Science and New Updates in Drug Formulation & Bioavailability meetings are coming up soon. We asked Michael Linnell, project manager for Life Science Sweden’s event portfolio, a few short questions.
-
Bioarctic granted Japanese patent for Parkinson’s disease candidate
Bioarctic has been granted a Japanese patent for its antibodies targeting Parkinson’s disease.
-
“Unfortunately, we are not strong when it comes to conducting clinical trials”
The number of company-initiated clinical trials conducted in Sweden has been declining in recent years. In mid-March, a government inquiry was presented that aimed to find answers and solutions to this downward trend. One of the proposals was a stable, sustainable and funded model for collaboration.
-
Studie: Musiklyssnande celler frigjorde insulin hos rockande möss
Kan celler designade för att producera insulin och en gammal rockdänga vara receptet på en behandling av diabetes? Det är något forskare i Schweiz tittat närmare på.
-
Small robots to deliver pharmaceuticals to the body
Robots that can operate inside the body and a platform that combines ultrasound with AI. These are a couple of the technologies that have qualified for a list that aims to promote sustainable entrepreneurship.
-
Double up for Korbinian Löbmann
This year, Korbinian Löbmann will moderate the New Updates in Drug Formulation & Bioavailability meeting in Copenhagen for the fifth time. Furthermore, he will also moderate The Future of Swedish & Danish Life Science congress in Lund for the first time.
-
Anna Törner: ”Jobbar på att ta över världen!”
Det är mer framgångsrikt att våga mycket, än att redan från början döma ut sig själv som otillräcklig, skriver Anna Törner i en krönika.
-
Han uppfann teknologin bakom Bactiguard: ”Brukar kalla det vårt eget Coca-Cola-recept"
Det tog många år och otaliga misslyckade experiment i labbet. Men till slut hittade Billy Södervall ett sätt att blanda ädelmetaller som konkurrenter än idag, flera decennier senare, förgäves försöker kopiera. I september fyller uppfinnaren 80 år – och
-
CROs in drug development: "We use our expertise to speed up the process
Consultancy firms have become an increasingly important part of drug development. “It’s a trend and a business model that works, and we see no indication that it will change,” says Helena Lüning of the industry organisation ASCRO.
-
A billion-dollar acquisition makes Novo Nordisk even bigger in obesity
Danish pharmaceutical giant Novo Nordisk acquires Montreal-based Inversago Pharma, which develops treatments for obesity and diabetes.
-
Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president
In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According to the reporter Theo Baker, who first reported the story, Tessier-Lavigne “rewarded the winners and punished the losers”. Here is the background of the story which has shaken the American scientific community over the summer.
-
Uppsala-based company wins important patent dispute – but the decision is subject to appeal
A US district court has ruled in favour of Orexo in a dispute over the patent protecting the Swedish company’s drug Zubsolv, developed for treating patients with opioid addiction. However, the opposing party, the Indian company Sun, is not giving up and has filed an appeal.
-
Stanfords rektor avgår efter anklagelser om forskningsfusk
Mitt i sommaren meddelade neuroforskaren Marc Tessier-Lavigne att han skulle lämna sin post som rektor för Stanford efter anklagelser om manipulerade studiedata. ”Han belönade vinnarna och straffade förlorarna”, säger reportern som avslöjade honom. Här är bakgrunden till vad som fick den uppburne forskaren på fall.
-
Han är ny CFO på Peptonic
Medtech-bolaget Peptonic Medical har nu rekryterat Albert Lindgren till Chief Financial Officer (CFO) för företaget.
-
Oncozenge pausar utveckling av smärtläkemedel för cancerpatienter: "Det är med tungt hjärta"
Envisa problem med tablettformuleringen gör att Oncozenge tvingas pausa utvecklingen av sin läkemedelskandidat Bupizenge. Behovet av kapital är stort och nu undersöks olika möjligheter att rädda projektet och undvika likvidation av bolaget.
-
AI-stödd mammografi hittade fler cancerfall i studie
Screening med hjälp av AI hittade fler bröstcancerfall och minskade arbetsbördan kraftigt jämfört med sedvanlig röntgengranskning av två radiologer i en studie från Lunds universitet.
BREAKING